| Name | Title | Contact Details |
|---|
Ameriflo is a global centrifugal pump manufacturer specializing in third party certified fire protection. Ameriflo manufactures equipment for the Commercial, Industrial & Municipal markets worldwide.
Perimeter Solutions is a global specialty chemicals company based in Clayton, Missouri, established in 1963. The company focuses on two main areas: fire safety solutions and lubricant additives. It is a market leader in both sectors, particularly known for its wildfire retardants, firefighting foams, and industrial fire suppressants. Perimeter Solutions offers a range of products, including water-enhancing gels and preventative fire retardants, catering to government agencies, municipalities, and industrial clients worldwide. In addition to fire safety, Perimeter Solutions specializes in niche engine oil additives, holding a significant market share in this area. These additives improve lubricant performance for both automotive and industrial applications. The company is publicly traded under the ticker PRM and is co-founded by Nick Howley, who also chairs the company. With a strong emphasis on innovation and a robust manufacturing and distribution network, Perimeter Solutions positions itself as a premier provider of chemical solutions in its industries.
Bridge Specialty Group, LLC was launched in February 2021 by Brown & Brown, Inc. to encompass its broad portfolio of wholesale insurance businesses and is focused on bringing the power of its collective size and specialty to the wholesale brokerage marketplace. Composed of more than 25 boutique brands, Bridge Specialty Group is creating a more seamless way to connect the varying needs of our retail partners with the market clout and talents of our wholesale entities. To learn more about Bridge Specialty Group and our team of niche-focused brands, visit our website at bridgespecialtygroup.com.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.